DOI record:
{
"DOI": "10.1080/14740338.2025.2471509",
"ISSN": [
"1474-0338",
"1744-764X"
],
"URL": "http://dx.doi.org/10.1080/14740338.2025.2471509",
"alternative-id": [
"10.1080/14740338.2025.2471509"
],
"assertion": [
{
"label": "Peer Review Statement",
"name": "peerreview_statement",
"order": 1,
"value": "The publishing and review policy for this title is described in its Aims & Scope."
},
{
"URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieds20",
"label": "Aim & Scope",
"name": "aims_and_scope_url",
"order": 2,
"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieds20"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Received",
"name": "received",
"order": 0,
"value": "2024-07-05"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Revised",
"name": "revised",
"order": 1,
"value": "2024-10-17"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Accepted",
"name": "accepted",
"order": 2,
"value": "2024-10-18"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Published",
"name": "published",
"order": 3,
"value": "2025-02-26"
}
],
"author": [
{
"affiliation": [
{
"name": "Chongqing Medical University",
"place": [
"Chongqing, China"
]
}
],
"family": "Gao",
"given": "Caixia",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Chongqing Medical University",
"place": [
"Chongqing, China"
]
}
],
"family": "Liu",
"given": "Zhihui",
"sequence": "additional"
},
{
"ORCID": "https://orcid.org/0000-0002-1651-591X",
"affiliation": [
{
"name": "Chongqing Medical University",
"place": [
"Chongqing, China"
]
}
],
"authenticated-orcid": false,
"family": "Zou",
"given": "Zhen",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Chongqing Medical University",
"place": [
"Chongqing, China"
]
}
],
"family": "Mao",
"given": "Lejiao",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Chongqing Medical University",
"place": [
"Chongqing, China"
]
}
],
"family": "Zhang",
"given": "Jun",
"sequence": "additional"
}
],
"container-title": "Expert Opinion on Drug Safety",
"container-title-short": "Expert Opinion on Drug Safety",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"www.tandfonline.com"
]
},
"created": {
"date-parts": [
[
2025,
2,
27
]
],
"date-time": "2025-02-27T03:03:32Z",
"timestamp": 1740625412000
},
"deposited": {
"date-parts": [
[
2025,
2,
27
]
],
"date-time": "2025-02-27T03:03:58Z",
"timestamp": 1740625438000
},
"indexed": {
"date-parts": [
[
2025,
2,
27
]
],
"date-time": "2025-02-27T05:33:26Z",
"timestamp": 1740634406437,
"version": "3.38.0"
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2025,
2,
26
]
]
},
"language": "en",
"link": [
{
"URL": "https://www.tandfonline.com/doi/pdf/10.1080/14740338.2025.2471509",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "301",
"original-title": [],
"prefix": "10.1080",
"published": {
"date-parts": [
[
2025,
2,
26
]
]
},
"published-online": {
"date-parts": [
[
2025,
2,
26
]
]
},
"publisher": "Informa UK Limited",
"reference": [
{
"DOI": "10.1056/NEJMoa2208822",
"doi-asserted-by": "publisher",
"key": "e_1_3_8_3_1"
},
{
"DOI": "10.1038/s41591-021-01283-z",
"article-title": "Post-acute COVID-19 syndrome",
"author": "Nalbandian A.",
"doi-asserted-by": "crossref",
"first-page": "601",
"issue": "4",
"journal-title": "Nat Med",
"key": "e_1_3_8_4_1",
"unstructured": "Nalbandian, A., et al., Post-acute COVID-19 syndrome. Nat Med, 2021. 27(4): p. 601–615.",
"volume": "27",
"year": "2021"
},
{
"DOI": "10.15585/mmwr.mm7251a1",
"doi-asserted-by": "crossref",
"key": "e_1_3_8_5_1",
"unstructured": "Smith D.J. A. Lambrou and P. Patel SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals. MMWR Morb Mortal Wkly Rep 2023. 72(51): p. 1357–1364."
},
{
"DOI": "10.1038/s41573-023-00672-y",
"article-title": "Therapeutic strategies for COVID-19: progress and lessons learned",
"author": "Li G.",
"doi-asserted-by": "crossref",
"first-page": "449",
"issue": "6",
"journal-title": "Nat Rev Drug Discov",
"key": "e_1_3_8_6_1",
"unstructured": "Li, G., et al., Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov, 2023. 22(6): p. 449–475.",
"volume": "22",
"year": "2023"
},
{
"DOI": "10.1021/acs.accounts.2c00735",
"doi-asserted-by": "publisher",
"key": "e_1_3_8_7_1"
},
{
"author": "Agarwal A.",
"first-page": "m3379",
"key": "e_1_3_8_8_1",
"unstructured": "Agarwal, A., et al., A living WHO guideline on drugs for covid-19. Bmj, 2020. 370: p. m3379.",
"volume-title": "A living WHO guideline on drugs for covid-19",
"year": "2020"
},
{
"key": "e_1_3_8_9_1",
"unstructured": "Owen D.R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 2021. 374(6575): p. 1586–1593."
},
{
"DOI": "10.1016/j.jmgm.2021.108042",
"article-title": "Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease",
"author": "Macchiagodena M.",
"doi-asserted-by": "crossref",
"first-page": "108042",
"journal-title": "J Mol Graph Model",
"key": "e_1_3_8_10_1",
"unstructured": "Macchiagodena, M., M. Pagliai, and P. Procacci, Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease. J Mol Graph Model, 2022. 110: p. 108042.",
"volume": "110",
"year": "2022"
},
{
"DOI": "10.1056/NEJMoa2118542",
"doi-asserted-by": "publisher",
"key": "e_1_3_8_11_1"
},
{
"DOI": "10.15585/mmwr.mm7148e2",
"doi-asserted-by": "crossref",
"key": "e_1_3_8_12_1",
"unstructured": "Shah M.M. et al. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States April-September 2022. MMWR Morb Mortal Wkly Rep 2022. 71(48): p. 1531–1537."
},
{
"DOI": "10.1007/s40265-022-01692-5",
"article-title": "Nirmatrelvir Plus Ritonavir: First Approval",
"author": "Lamb Y.N.",
"doi-asserted-by": "crossref",
"first-page": "585",
"issue": "5",
"journal-title": "Drugs",
"key": "e_1_3_8_13_1",
"unstructured": "Lamb, Y.N., Nirmatrelvir Plus Ritonavir: First Approval. Drugs, 2022. 82(5): p. 585–591.",
"volume": "82",
"year": "2022"
},
{
"DOI": "10.1021/jacs.3c12678",
"article-title": "A Chemical Strategy for the Degradation of the Main Protease of SARS-CoV-2 in Cells",
"author": "Sang X.",
"doi-asserted-by": "crossref",
"first-page": "27248",
"issue": "50",
"journal-title": "J Am Chem Soc",
"key": "e_1_3_8_14_1",
"unstructured": "Sang, X., et al., A Chemical Strategy for the Degradation of the Main Protease of SARS-CoV-2 in Cells. J Am Chem Soc, 2023. 145(50): p. 27248–27253.",
"volume": "145",
"year": "2023"
},
{
"DOI": "10.1093/cid/ciac180",
"article-title": "Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs",
"author": "Saravolatz L.D.",
"doi-asserted-by": "crossref",
"first-page": "165",
"issue": "1",
"journal-title": "Clin Infect Dis",
"key": "e_1_3_8_15_1",
"unstructured": "Saravolatz, L.D., S. Depcinski, and M. Sharma, Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clin Infect Dis, 2023. 76(1): p. 165–171.",
"volume": "76",
"year": "2023"
},
{
"DOI": "10.1080/14756366.2021.1954919",
"article-title": "Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332",
"author": "Pavan M.",
"doi-asserted-by": "crossref",
"first-page": "1646",
"issue": "1",
"journal-title": "J Enzyme Inhib Med Chem",
"key": "e_1_3_8_16_1",
"unstructured": "Pavan, M., et al., Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J Enzyme Inhib Med Chem, 2021. 36(1): p. 1646–1650.",
"volume": "36",
"year": "2021"
},
{
"DOI": "10.3389/fphar.2022.954359",
"article-title": "Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system",
"author": "Guo Q.",
"doi-asserted-by": "crossref",
"first-page": "954359",
"journal-title": "Front Pharmacol",
"key": "e_1_3_8_17_1",
"unstructured": "Guo, Q., et al., Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system. Front Pharmacol, 2022. 13: p. 954359.",
"volume": "13",
"year": "2022"
},
{
"DOI": "10.1002/adma.202311537",
"article-title": "ACE2 Receptor-Targeted Inhaled Nanoemulsions Inhibit SARS-CoV-2 and Attenuate Inflammatory Responses",
"author": "Wang H.",
"doi-asserted-by": "crossref",
"first-page": "e2311537",
"journal-title": "Adv Mater",
"key": "e_1_3_8_18_1",
"unstructured": "Wang, H., et al., ACE2 Receptor-Targeted Inhaled Nanoemulsions Inhibit SARS-CoV-2 and Attenuate Inflammatory Responses. Adv Mater, 2024: p. e2311537.",
"year": "2024"
},
{
"DOI": "10.1038/s41579-020-00459-7",
"doi-asserted-by": "publisher",
"key": "e_1_3_8_19_1"
},
{
"author": "Fumagalli V.",
"key": "e_1_3_8_20_1",
"unstructured": "Fumagalli, V. and M. Iannacone, The interplay of drug therapeutics and immune responses to SARS-CoV-2. Cell Mol Immunol, 2023.",
"volume-title": "The interplay of drug therapeutics and immune responses to SARS-CoV-2",
"year": "2023"
},
{
"DOI": "10.1093/cid/ciac443",
"article-title": "Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients",
"author": "Najjar-Debbiny R.",
"doi-asserted-by": "crossref",
"first-page": "e342",
"issue": "3",
"journal-title": "Clin Infect Dis",
"key": "e_1_3_8_21_1",
"unstructured": "Najjar-Debbiny, R., et al., Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis, 2023. 76(3): p. e342–e349.",
"volume": "76",
"year": "2023"
},
{
"DOI": "10.1038/s41392-023-01587-1",
"doi-asserted-by": "crossref",
"key": "e_1_3_8_22_1",
"unstructured": "Zhang Y. et al. A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir. Signal Transduct Target Ther 2023. 8(1): p. 360."
},
{
"DOI": "10.3389/fphar.2022.938552",
"article-title": "Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system",
"author": "Jeong E.",
"doi-asserted-by": "crossref",
"first-page": "938552",
"journal-title": "Front Pharmacol",
"key": "e_1_3_8_23_1",
"unstructured": "Jeong, E., et al., Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. Front Pharmacol, 2022. 13: p. 938552.",
"volume": "13",
"year": "2022"
},
{
"DOI": "10.1016/j.jinf.2022.09.027",
"article-title": "Efficacy and safety of Paxlovid for COVID-19:a meta-analysis",
"author": "Zheng Q.",
"doi-asserted-by": "crossref",
"first-page": "66",
"issue": "1",
"journal-title": "J Infect",
"key": "e_1_3_8_24_1",
"unstructured": "Zheng, Q., et al., Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect, 2023. 86(1): p. 66–117.",
"volume": "86",
"year": "2023"
},
{
"DOI": "10.1002/jmv.28471",
"article-title": "Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis",
"author": "Cheema H.A.",
"doi-asserted-by": "crossref",
"first-page": "e28471",
"issue": "2",
"journal-title": "J Med Virol",
"key": "e_1_3_8_25_1",
"unstructured": "Cheema, H.A., et al., Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol, 2023. 95(2): p. e28471.",
"volume": "95",
"year": "2023"
},
{
"DOI": "10.1080/07853890.2022.2034936",
"article-title": "Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis",
"author": "Wen W.",
"doi-asserted-by": "crossref",
"first-page": "516",
"issue": "1",
"journal-title": "Ann Med",
"key": "e_1_3_8_26_1",
"unstructured": "Wen, W., et al., Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med, 2022. 54(1): p. 516–523.",
"volume": "54",
"year": "2022"
},
{
"DOI": "10.1002/ohn.278",
"doi-asserted-by": "publisher",
"key": "e_1_3_8_27_1"
},
{
"DOI": "10.1002/jmv.28732",
"article-title": "Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis",
"author": "Tian F.",
"doi-asserted-by": "crossref",
"first-page": "e28732",
"issue": "4",
"journal-title": "J Med Virol",
"key": "e_1_3_8_28_1",
"unstructured": "Tian, F., Z. Chen, and Q. Feng, Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol, 2023. 95(4): p. e28732.",
"volume": "95",
"year": "2023"
},
{
"key": "e_1_3_8_29_1",
"unstructured": "Pfizer. Nirmatrelvir/ritonavir Paxlovid. 2022-2-7]; Available from: https://www.pfizermedicalinformation.cn/products/package-insert/paxlovid."
},
{
"DOI": "10.1080/14740338.2022.2045945",
"doi-asserted-by": "publisher",
"key": "e_1_3_8_30_1"
},
{
"author": "Deng Z.",
"key": "e_1_3_8_31_1",
"unstructured": "Deng, Z., et al., Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study. CNS Neurosci Ther, 2023.",
"volume-title": "Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study",
"year": "2023"
},
{
"key": "e_1_3_8_32_1",
"unstructured": "FDA. FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. 2004-1]; Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files."
},
{
"DOI": "10.1001/jamaneurol.2020.1127",
"doi-asserted-by": "crossref",
"key": "e_1_3_8_33_1",
"unstructured": "Mao L. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan China. JAMA Neurol 2020. 77(6): p. 683–690."
},
{
"DOI": "10.1038/s41591-022-02001-z",
"article-title": "Long-term neurologic outcomes of COVID-19",
"author": "Xu E.",
"doi-asserted-by": "crossref",
"first-page": "2406",
"issue": "11",
"journal-title": "Nat Med",
"key": "e_1_3_8_34_1",
"unstructured": "Xu, E., Y. Xie, and Z. Al-Aly, Long-term neurologic outcomes of COVID-19. Nat Med, 2022. 28(11): p. 2406–2415.",
"volume": "28",
"year": "2022"
},
{
"DOI": "10.1016/S2215-0366(22)00260-7",
"article-title": "Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients",
"author": "Taquet M.",
"doi-asserted-by": "crossref",
"first-page": "815",
"issue": "10",
"journal-title": "Lancet Psychiatry",
"key": "e_1_3_8_35_1",
"unstructured": "Taquet, M., et al., Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry, 2022. 9(10): p. 815–827.",
"volume": "9",
"year": "2022"
},
{
"DOI": "10.1038/s41586-022-05542-y",
"article-title": "SARS-CoV-2 infection and persistence in the human body and brain at autopsy",
"author": "Stein S.R.",
"doi-asserted-by": "crossref",
"first-page": "758",
"issue": "7941",
"journal-title": "Nature",
"key": "e_1_3_8_36_1",
"unstructured": "Stein, S.R., et al., SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 2022. 612(7941): p. 758–763.",
"volume": "612",
"year": "2022"
},
{
"DOI": "10.1002/jcla.24403",
"article-title": "Neurological manifestations in patients with COVID-19: A systematic review and meta-analysis",
"author": "Mahdizade Ari M.",
"doi-asserted-by": "crossref",
"first-page": "e24403",
"issue": "5",
"journal-title": "J Clin Lab Anal",
"key": "e_1_3_8_37_1",
"unstructured": "Mahdizade Ari, M., et al., Neurological manifestations in patients with COVID-19: A systematic review and meta-analysis. J Clin Lab Anal, 2022. 36(5): p. e24403.",
"volume": "36",
"year": "2022"
},
{
"DOI": "10.1016/j.dsx.2021.04.026",
"article-title": "Cerebral venous thrombosis in COVID-19",
"author": "Ghosh R.",
"doi-asserted-by": "crossref",
"first-page": "1039",
"issue": "3",
"journal-title": "Diabetes Metab Syndr",
"key": "e_1_3_8_38_1",
"unstructured": "Ghosh, R., et al., Cerebral venous thrombosis in COVID-19. Diabetes Metab Syndr, 2021. 15(3): p. 1039–1045.",
"volume": "15",
"year": "2021"
},
{
"DOI": "10.1093/brain/awac270",
"doi-asserted-by": "crossref",
"key": "e_1_3_8_39_1",
"unstructured": "Soung A.L. et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain 2022. 145(12): p. 4193–4201."
},
{
"DOI": "10.1073/pnas.2200960119",
"article-title": "Morphological, cellular, and molecular basis of brain infection in COVID-19 patients",
"author": "Crunfli F.",
"doi-asserted-by": "crossref",
"first-page": "e2200960119",
"issue": "35",
"journal-title": "Proc Natl Acad Sci U S A",
"key": "e_1_3_8_40_1",
"unstructured": "Crunfli, F., et al., Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci U S A, 2022. 119(35): p. e2200960119.",
"volume": "119",
"year": "2022"
},
{
"DOI": "10.1016/j.bbi.2021.12.007",
"article-title": "SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties",
"author": "Frank M.G.",
"doi-asserted-by": "crossref",
"first-page": "267",
"journal-title": "Brain Behav Immun",
"key": "e_1_3_8_41_1",
"unstructured": "Frank, M.G., et al., SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties. Brain Behav Immun, 2022. 100: p. 267–277.",
"volume": "100",
"year": "2022"
},
{
"key": "e_1_3_8_42_1",
"unstructured": "Needham E.J. et al. Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain 2022. 145(11): p. 4097–4107."
},
{
"key": "e_1_3_8_43_1",
"unstructured": "Paterson R.W. et al. The emerging spectrum of COVID-19 neurology: clinical radiological and laboratory findings. Brain 2020. 143(10): p. 3104–3120."
},
{
"DOI": "10.1016/S2215-0366(20)30203-0",
"article-title": "Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic",
"author": "Rogers J.P.",
"doi-asserted-by": "crossref",
"first-page": "611",
"issue": "7",
"journal-title": "Lancet Psychiatry",
"key": "e_1_3_8_44_1",
"unstructured": "Rogers, J.P., et al., Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry, 2020. 7(7): p. 611–627.",
"volume": "7",
"year": "2020"
},
{
"article-title": "Neuropsychiatric aspects of long COVID: A comprehensive review",
"author": "Kubota T.",
"journal-title": "Psychiatry Clin Neurosci",
"key": "e_1_3_8_45_1",
"unstructured": "Kubota, T., N. Kuroda, and D. Sone, Neuropsychiatric aspects of long COVID: A comprehensive review. Psychiatry Clin Neurosci, 2022.",
"year": "2022"
},
{
"author": "Hartung T.J.",
"first-page": "101651",
"key": "e_1_3_8_46_1",
"unstructured": "Hartung, T.J., et al., Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. EClinicalMedicine, 2022. 53: p. 101651.",
"volume-title": "Fatigue and cognitive impairment after COVID-19: A prospective multicentre study",
"year": "2022"
},
{
"DOI": "10.1038/s41380-022-01632-5",
"article-title": "Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings",
"author": "de Paula J.J.",
"doi-asserted-by": "crossref",
"first-page": "553",
"issue": "2",
"journal-title": "Mol Psychiatry",
"key": "e_1_3_8_47_1",
"unstructured": "de Paula, J.J., et al., Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings. Mol Psychiatry, 2023. 28(2): p. 553–563.",
"volume": "28",
"year": "2023"
},
{
"article-title": "Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS",
"author": "Li M.",
"journal-title": "Pharmaceuticals (Basel)",
"key": "e_1_3_8_48_1",
"unstructured": "Li, M., et al., Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS. Pharmaceuticals (Basel), 2022. 15(12).",
"year": "2022"
},
{
"DOI": "10.1001/jamanetworkopen.2022.7970",
"doi-asserted-by": "crossref",
"key": "e_1_3_8_49_1",
"unstructured": "Conti V. et al. Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review. JAMA Netw Open 2022. 5(4): p. e227970."
},
{
"DOI": "10.1038/s41598-021-91953-2",
"article-title": "Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain",
"author": "Cantudo-Cuenca M.D.",
"doi-asserted-by": "crossref",
"first-page": "12414",
"issue": "1",
"journal-title": "Sci Rep",
"key": "e_1_3_8_50_1",
"unstructured": "Cantudo-Cuenca, M.D., et al., Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. Sci Rep, 2021. 11(1): p. 12414.",
"volume": "11",
"year": "2021"
},
{
"DOI": "10.1080/17425255.2024.2339397",
"article-title": "Adverse events related to drug-drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review",
"author": "Conti V.",
"doi-asserted-by": "crossref",
"first-page": "275",
"issue": "4",
"journal-title": "Expert Opin Drug Metab Toxicol",
"key": "e_1_3_8_51_1",
"unstructured": "Conti, V., et al., Adverse events related to drug-drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review. Expert Opin Drug Metab Toxicol, 2024. 20(4): p. 275–292.",
"volume": "20",
"year": "2024"
},
{
"DOI": "10.1007/s00228-022-03370-7",
"article-title": "COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed",
"author": "Yalcin N.",
"doi-asserted-by": "crossref",
"first-page": "1697",
"issue": "10",
"journal-title": "Eur J Clin Pharmacol",
"key": "e_1_3_8_52_1",
"unstructured": "Yalcin, N. and K. Allegaert, COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed. Eur J Clin Pharmacol, 2022. 78(10): p. 1697–1701",
"volume": "78",
"year": "2022"
}
],
"reference-count": 50,
"references-count": 50,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.tandfonline.com/doi/full/10.1080/14740338.2025.2471509"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Effects of Nirmatrelvir/ritonavir (paxlovid) on the nervous system: analysis on adverse events released by FDA",
"type": "journal-article",
"update-policy": "https://doi.org/10.1080/tandf_crossmark_01"
}
